Startup Spotlight: UNC-linked startup is giving hope to those with hemophilia
GeneVentiv Therapeutics is developing the first universal gene therapy for all types of hemophilia, including the most difficult cases. Let’s take a look.
Read More
geneventiv
Raleigh’s GeneVentiv Therapeutics signs deal with UNC for potential hemophilia therapy
GeneVentiv Therapeutics, Inc., a gene therapy developer, announced a license agreement with the University of North Carolina at Chapel Hill for a patent-pending, gene therapy for hemophilia.
Read More
